Study Makes MOVES For Chondroitin/Glucosamine On Osteoarthritis Pain
This article was originally published in The Tan Sheet
Executive Summary
At six months, 79.7% of the moderate-to-severe patients in the supplementation group and 79.2% in the celecoxib group fulfilled pain reduction criteria, the primary outcome measured in the Multicenter Osteoarthritis InterVEntion trial with SYSADOA.
You may also be interested in...
‘Vast Weight’ Of Evidence Fails To Tip Scale Against Joint Health Claims
A U.S. circuit court affirms a ruling that consumers from California, Illinois, New York, Ohio and Pennsylvania did not adequately plead falsity of the allegedly misleading marketing claims by GNC and Rite Aid.
‘Vast Weight’ Of Evidence Fails To Tip Scale Against Joint Health Claims
A U.S. circuit court affirms a ruling that consumers from California, Illinois, New York, Ohio and Pennsylvania did not adequately plead falsity of the allegedly misleading marketing claims by GNC and Rite Aid.
Efficacy Evidence Opens Door To Sell More Doctors On Joint Health Supplements
Some doctors need more than impressive study results to change their routines, says Nicholas DiNubile, an orthopedic surgeon and a proponent of chondroitin/glucosamine supplementation for osteoarthritis patients. The patients, he says, often are asking about options to treatment with NSAIDs.